[Dihydroergotamine as a nasal spray in the therapy of migraine attacks. Efficacy and tolerance].
In an open multicentre study in Switzerland, the dihydroergotamine nasal spray was studied for its efficacy and tolerability in the treatment of acute migraine attacks (common and classical migraine--one attack each patient) in a total of 904 patients. In the global assessment, 76.8% of all the patients reported good efficacy (freedom from pain, less pain or shorter duration of pain). When the nasal spray was used already in the prodromal phase, good efficacy could be obtained by 90 (63%) of 143 patients. 18.1% of all the patients treated--more frequently those who obtained no beneficial effect and/or who took additional medication during the migraine attack--reported one or more--minor side-effects such as local nasal irritation (congestion, burning or stinging), nausea, dizziness and vomiting. 3.9% of the patients said they would not use the spray again because of the side effects.
Jenzer
G
G
Spezialarzt FMH für Neurologie, Langenthal.
Bremgartner
M F
MF
D000281:Administration, Intranasal; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D004087:Dihydroergotamine / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D015337:Multicenter Studies as Topic; D009330:Nebulizers and Vaporizers
D004087:Dihydroergotamine
Dihydroergotamin als Nasalspray in der Therapie des Migräneanfalls. Wirksamkeit und Verträglichkeit.